Patents by Inventor John Chaber

John Chaber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Niraparib Compositions
    Publication number: 20230416223
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Application
    Filed: May 1, 2023
    Publication date: December 28, 2023
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Niraparib compositions
    Patent number: 11673877
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: June 13, 2023
    Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Niraparib Compositions
    Publication number: 20210403448
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Application
    Filed: June 4, 2021
    Publication date: December 30, 2021
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • Niraparib compositions
    Patent number: 11091459
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 17, 2021
    Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.
    Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
  • PEDIATRIC NIRAPARIB FORMULATIONS AND PEDIATRIC TREATMENT METHODS
    Publication number: 20210030735
    Abstract: The present invention relates to methods of treating cancer in pediatric subjects comprising administration of compound niraparib in a suitable oral dosage form and optionally in combination with a second therapeutic agent such as a PD-1 inhibitor.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 4, 2021
    Inventors: Simon McGurk, David Lust, Kevin Johnston, Duantel Verwijs, Aaron Nelson, Clare Medendorp, Melanie Ronsheim, John Chaber, Steve Ruddy, Katie Poutsiaka, Danny van Hoorn, Aileen Dowling
  • Niraparib compositions
    Patent number: 10829476
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 10, 2020
    Assignee: Tesaro, Inc.
    Inventors: George Wu, John Chaber
  • NIRAPARIB COMPOSITIONS
    Publication number: 20200017462
    Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of iraparib.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: George Wu, John Chaber
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
    Publication number: 20150190413
    Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 9, 2015
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: John CHABER, Petr KUZMA, Agis KYDONIEUS
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
    Publication number: 20090214634
    Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.
    Type: Application
    Filed: November 26, 2008
    Publication date: August 27, 2009
    Inventors: John Chaber, Petr Kuzma, Agis Kydonieus